Dentsply Sirona Inc. (XRAY) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Dentsply Sirona Inc. (XRAY) stock forecast summary
On Oct. 16, 2026, XRAY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
Dentsply Sirona Inc. is a small-cap company with a market capitalization of $1.76B.
For XRAY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.7%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, XRAY included.
Follow XRAY freeXRAY price chart and AI forecast
How XRAY ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Dentsply Sirona Inc. (XRAY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Dental Equipment & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | XRAY | Rank |
|---|---|---|
| Market Cap | $1.76B | – |
| P/B Ratio | 1.30x | – |
| Dividend Yield | 7.27% | – |
| EPS | $-2.60 | – |
| Book Value/Share | $6.78 | – |
| Revenue/Share | $18.27 | – |
| FCF/Share | $0.72 | – |
Profitability & Margins
| Metric | XRAY | Rank |
|---|---|---|
| ROE | -40.4% | – |
| ROA | -10.5% | – |
| ROIC | -7.7% | – |
| Gross Margin | 49.5% | – |
| Operating Margin | -8.5% | – |
| Net Margin | -15.0% | – |
| EBT Margin | -9.5% | – |
| Tax Rate | -57.6% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | XRAY | Rank |
|---|---|---|
| Current Ratio | 1.63x | – |
| Quick Ratio | 1.07x | – |
| D/E Ratio | 2.85x | – |
| Financial Leverage | 3.85x | – |
| Interest Coverage | 1.9x | – |
| Working Capital | $743M | – |
Cash Flow
| Metric | XRAY | Rank |
|---|---|---|
| Operating Cash Flow | $319M | – |
| Free Cash Flow | $143M | – |
| Capital Spending | -$176M | – |
| OCF Growth YoY | 12.7% | – |
| FCF Growth YoY | 3.6% | – |
| FCF/Sales | 3.9% | – |
| CapEx/Sales | 4.8% | – |
Operational Efficiency
| Metric | XRAY | Rank |
|---|---|---|
| Asset Turnover | 0.70x | – |
| Inventory Turnover | 2.8x | – |
| Fixed Assets Turnover | 4.3x | – |
| Days Inventory | 132 days | – |
| Payables Period | 52 days | – |
Income Statement
| Metric | XRAY | Rank |
|---|---|---|
| Total Revenue | $3.64B | – |
| Operating Income | -$310M | – |
| Net Income | -$546M | – |
| R&D Expense | $166M | – |
| SG&A Expense | $1.45B | – |
| Cost of Goods Sold | $1.84B | – |
Dividend & Shareholder Information
| Metric | XRAY | Rank |
|---|---|---|
| Dividends Per Share | $0.64 | – |
| Shares Outstanding | 199M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.93B | 37.0% of assets |
| Cash & Short-term Investments | $239M | 4.6% of assets |
| Inventory | $665M | 12.8% of assets |
| Total Liabilities | $3.85B | 74.0% of assets |
| Short-term Debt | $925M | 17.8% of assets |
XRAY quarterly financials and insider trading
Dentsply Sirona Inc. (XRAY) industry peers
Companies classified under the same SEC industry code as Dentsply Sirona Inc. (Dental Equipment & Supplies): 4 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere XRAY sits on the market map
Dentsply Sirona Inc. (XRAY) stock news
Loading...
Dentsply Sirona Inc. (XRAY) stock forecast FAQ
What is the Dentsply Sirona Inc. (XRAY) stock forecast?
On Oct. 16, 2026, XRAY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Dentsply Sirona Inc. stock predictions?
For XRAY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Dentsply Sirona Inc. forecasts updated?
Dentsply Sirona Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Dentsply Sirona Inc.'s industry peers?
4 issuers in our coverage, XRAY included, share the SEC industry code Dental Equipment & Supplies. The largest are: Envista Holdings Corp (NVST), Dror Ortho-Design, Inc. (DROR), Sonendo, Inc. (SONX).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.